Literature DB >> 22181034

The use of adrenaline autoinjectors by children and teenagers.

L Noimark1, J Wales, G Du Toit, C Pastacaldi, D Haddad, J Gardner, W Hyer, G Vance, C Townshend, M Alfaham, P D Arkwright, R Rao, S Kapoor, A Summerfield, J O Warner, G Roberts.   

Abstract

BACKGROUND: Although adrenaline is recommended as first line treatment for anaphylaxis, it is often not utilized. There has been a debate about when adrenaline autoinjectors should be prescribed and how many should be dispensed.
OBJECTIVES: To see how many adrenaline autoinjectors were used during anaphylactic reactions and to determine why they were not used in situations where they were clinically indicated.
METHODS: Patients were recruited prospectively at 14 paediatric allergy clinics throughout UK. Participants completed a questionnaire covering demographic data, atopic status and details of allergic reactions in the previous year and reasons for using more than one device.
RESULTS: A total of 969 patients were recruited of whom 466 (48.1%, 95% CI: 37.9-58.2) had had at least one reaction in the previous year; 245 (25.3%, 95% CI: 16.2-34.4) of these reactions were anaphylaxis. An adrenaline autoinjector was used by 41 (16.7%, 95% CI: 11.7-21.3) participants experiencing anaphylaxis. Thirteen participants received more than one dose of adrenaline, for nine of these a health professional gave at least one. The commonest reasons for using more than one were severe breathing difficulties (40%), lack of improvement with first dose (20%) and miss-firing (13.3%). The commonest reasons for not using adrenaline in anaphylaxis were 'thought adrenaline unnecessary' (54.4%) and 'unsure adrenaline necessary' (19.1%). Many with wheeze did not use their autoinjector. CONCLUSIONS AND CLINICAL RELEVANCE: Adrenaline is used by only a minority of patients experiencing anaphylaxis in the community. Thirteen of the 41 patients with anaphylaxis who used their autoinjector needed another dose of adrenaline. Further research is needed to consider how to best encourage the usage of adrenaline when clinically indicated in anaphylaxis.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22181034     DOI: 10.1111/j.1365-2222.2011.03912.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  20 in total

1.  How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients.

Authors:  Erminia Ridolo; Marcello Montagni; Laura Bonzano; Eleonora Savi; Silvia Peveri; Maria Teresa Costantino; Mariangiola Crivellaro; Giuseppina Manzotti; Carlo Lombardi; Marco Caminati; Cristoforo Incorvaia; Gianenrico Senna
Journal:  Intern Emerg Med       Date:  2015-05-20       Impact factor: 3.397

2.  Guidelines for Bystander First Aid 2016.

Authors:  Jen Heng Pek
Journal:  Singapore Med J       Date:  2017-07       Impact factor: 1.858

Review 3.  Emerging Therapies in Anaphylaxis: Alternatives to Intramuscular Administration of Epinephrine.

Authors:  Brittany Boswell; Susan A Rudders; Julie C Brown
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

Review 4.  Epidemiology of severe anaphylaxis: can we use population-based data to understand anaphylaxis?

Authors:  Paul J Turner; Dianne E Campbell
Journal:  Curr Opin Allergy Clin Immunol       Date:  2016-10

Review 5.  Evidence update for the treatment of anaphylaxis.

Authors:  Amy Dodd; Anna Hughes; Nicholas Sargant; Andrew F Whyte; Jasmeet Soar; Paul J Turner
Journal:  Resuscitation       Date:  2021-04-23       Impact factor: 5.262

6.  Self-administration of adrenaline for anaphylaxis during in-hospital food challenges improves health-related quality of life.

Authors:  Sarah Burrell; Nandinee Patel; Marta Vazquez-Ortiz; Dianne E Campbell; Audrey DunnGalvin; Paul J Turner
Journal:  Arch Dis Child       Date:  2020-09-18       Impact factor: 3.791

7.  Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012.

Authors:  Paul J Turner; M Hazel Gowland; Vibha Sharma; Despo Ierodiakonou; Nigel Harper; Tomaz Garcez; Richard Pumphrey; Robert J Boyle
Journal:  J Allergy Clin Immunol       Date:  2014-11-25       Impact factor: 10.793

8.  International consensus on (ICON) anaphylaxis.

Authors:  F Estelle R Simons; Ledit Rf Ardusso; M Beatrice Bilò; Victoria Cardona; Motohiro Ebisawa; Yehia M El-Gamal; Phil Lieberman; Richard F Lockey; Antonella Muraro; Graham Roberts; Mario Sanchez-Borges; Aziz Sheikh; Lynette P Shek; Dana V Wallace; Margitta Worm
Journal:  World Allergy Organ J       Date:  2014-05-30       Impact factor: 4.084

9.  Patients' ability to treat anaphylaxis using adrenaline autoinjectors: a randomized controlled trial.

Authors:  T Umasunthar; A Procktor; M Hodes; J G Smith; C Gore; H E Cox; T Marrs; H Hanna; K Phillips; C Pinto; P J Turner; J O Warner; R J Boyle
Journal:  Allergy       Date:  2015-04-16       Impact factor: 13.146

10.  Living with severe allergy: an Anaphylaxis Campaign national survey of young people.

Authors:  Allison Worth; Lynne Regent; Mark Levy; Carey Ledford; Mandy East; Aziz Sheikh
Journal:  Clin Transl Allergy       Date:  2013-01-22       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.